Industry Daily Summary
Industry Daily Summary: What Happened on October 15, 2026
Alentis, PinotBio pair up on claudin-1 cancer ADCs
Verastem also set out a succession plan for its chief executive role.
Today in brief
Alentis Therapeutics and South Korea’s PinotBio signed a research and licensing agreement to develop antibody-drug conjugates for cancers that express claudin-1.1 Alentis has an exclusive option to license PinotBio’s linkers and payloads. PinotBio is eligible for upfront, development, regulatory and commercial milestone payments, plus royalties on net sales.1
Verastem disclosed a plan for succession in its chief executive role.2
Also worth knowing
-
Alentis is evaluating two claudin-1 antibody-drug conjugates in Phase I/II trials. The FDA granted fast track designation to ALE.P02 for advanced or metastatic claudin-1-positive squamous tumors.1